Fandom Sports Esports App in Private Beta Testing

Vancouver, British Columbia–(Newsfile Corp. – July 6, 2020) – FANDOM SPORTS Media…

Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

TORONTO, June 30, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison

TORONTO, June 12, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19

VANCOUVER, British Columbia, June 04, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

IMC International Mining Corp. Announces CJL/Mat/Lake Area Results

Significant Copper and Gold Results from Rock Sampling VANCOUVER, BC / ACCESSWIRE…

Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19

TORONTO, June 03, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19

VANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives

TORONTO, May 13, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or…

Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial

VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…

Algernon Presents “The Science of Ifenprodil” on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD

ANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc.…